OKYO Pharma Limited (“OKYO” or the “Company”) Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease
LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a…
Richard Roths Media Announces $52 Million Dollar Investment Approval to Expand its AI-Driven Marketing Systems
Four Inc. Secures Spot on Washington Technology’s Top 100 Government Contractors List for 11th Consecutive Year
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Annual Results